サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：手足口病治療の世界市場 - 産業規模、シェア、動向、機会、予測：薬剤タイプ別、投与経路別、流通チャネル別、企業別、地域別（2017年～2027年）
市場調査レポート
商品コード
1166582

手足口病治療の世界市場 - 産業規模、シェア、動向、機会、予測：薬剤タイプ別、投与経路別、流通チャネル別、企業別、地域別（2017年～2027年）

Hand, Foot, and Mouth Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Drug Type, By Route of Administration, By Distribution Channel, By Company, and By Region
出版日: | 発行: TechSci Research | ページ情報: 英文 118 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

手足口病治療の世界市場 - 産業規模、シェア、動向、機会、予測：薬剤タイプ別、投与経路別、流通チャネル別、企業別、地域別（2017年～2027年）
出版日: 2022年12月01日
発行: TechSci Research
ページ情報: 英文 118 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の手足口病治療市場は、2023年から2027年の予測期間中に目覚ましい成長を遂げると予測されています。

主な要因としては、ウイルス感染症の発生件数の増加が含まれ、大規模な研究開発が世界的に市場の成長を促進していることが挙げられます。市場の成長を支えるその他の要因としては、研究開発活動への政府投資の増加、製薬メーカーのフットプリント拡大、発展したヘルスケアインフラ整備、大衆の意識向上、技術の進歩などが挙げられます。また、臨床試験段階にある手足口病治療薬のFDA承認の容易さは、手足口病治療市場の成長をさらに促進すると予想されています。

当レポートでは、世界の手足口病治療市場について調査し、セグメント別の分析、市場力学、企業プロファイルなどの情報を提供しています。

目次

第1章 製品概要

第2章 調査手法

第3章 世界の手足口病治療市場に対するCOVID-19の影響

第4章 VOC (顧客の声)

第5章 エグゼクティブサマリー

第6章 臨床試験分析

第7章 世界の手足口病治療市場の見通し

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 薬剤タイプ別（鎮痛剤、非ステロイド性抗炎症薬、ヌクレオシド類似体抗ウイルス薬）
    • 投与経路別（局所、経口、静脈内）
    • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
    • 企業別（2021年）
    • 地域別
  • 市場マップ

第8章 北米の手足口病治療市場の見通し

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 薬剤タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第9章 欧州の手足口病治療市場の見通し

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 薬剤タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第10章 アジア太平洋の手足口病治療市場の見通し

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 薬剤タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • アジア太平洋：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第11章 南米の手足口病治療市場の見通し

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 薬剤タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第12章 中東・アフリカの手足口病治療市場の見通し

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 薬剤タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第13章 市場力学

  • 促進要因
  • 課題

第14章 市場の動向と発展

第15章 競合情勢

  • Johnson & Johnson
  • GlaxoSmithKline plc.
  • Emergex Vaccines Holdings Ltd
  • Takeda Pharmaceutical Co Ltd
  • CJ HealthCare Corp.
  • Adimmune Corp

第16章 戦略的提言

目次
Product Code: 13003

The global hand, foot, and mouth disease treatment market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include growing incidences of viral infections, and extensive research and development are propelling the growth of the market, globally. Hand, foot, and mouth disease also abbreviated as HFMD is a contagious disease which is caused by enterovirus genus majorly Coxsackievirus A16 and enterovirus A71. These viruses are majorly detected in children below age 10 and is usually spread through skin-to-skin contact, airborne respiratory droplets or by saliva. The other factors supporting the market's growth are, the increasing government investments on R&D activities, growing footprint of pharmaceutical manufacturers, developed healthcare infrastructure, rising awareness among the masses, and technological advancements. Also, ease in FDA approvals for hand, foot, and mouth disease (HFMD) drugs in clinical trial phase is further projected to drive the growth of hand, foot, and mouth disease treatment market.

High Prevalence of Viral Infection

Viral infections are very common in children below age 10 as they have very low immunity, and they often tend to put their hands in mouth. Hand, foot, and mouth disease (HFMD) is caused by a virus from the Enterovirus genus, most commonly the coxsackievirus. These viruses are transmitted from infected person to other. Owing to the large patient pool due to HFMD, the demand for hand, foot and mouth disease treatment is upsurging. Moreover, growth of the health care industry due to the growing incidences of viruses across the globe is facilitating the market growth. For instance, from 2013-2019, 15,316,710 probable cases of HFMD were reported. Out of these, 787,197 (5*1%) were laboratory confirmed and 76,982 (0*5%) were severe.

Growing Awareness and Research

Over the past few years, increase in awareness among masses about the hand, foot and mouth diseases is seen. Various awareness programs are initiated by governments of different nations, which are propelling the growth of the market. Hand, foot, and mouth disease is widespread pediatric disease which occurs in children under the age of 5. Owing to the rise in number of patients suffering from HFMD, demand for the drug discovery research is rising. This, in turn, propels the market growth. For instance, according to Iranian Journal of Public Health, a study conducted from 2008 to 2015 revealed the incidence of HFMD grew rapidly from 86.59/100,000 in 2009 to 203.16/100,000 in 2014. Moreover, heavy investments by governments and market players on R&D activities and clinical trials, are bolstering the market growth.

Market Segmentation

The global hand, foot, and mouth disease treatment market is segmented into drug type, route of administration, distribution channel, and company. Based on drug type, the market is divided into pain relievers, non-steroidal anti-inflammatory drugs, and nucleoside analogue antivirals. Based on route of administration, the market is divided into topical, oral, and intravenous. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising research and development activities in the country.

Market Players

Johnson & Johnson, GlaxoSmithKline plc., Emergex Vaccines Holdings Ltd, Takeda Pharmaceutical Co Ltd, CJ HealthCare Corp., and Adimmune Corp are some of the leading companies operating in the market.

Report Scope:

In this report, global hand, foot, and mouth disease treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Hand, Foot, and Mouth Disease Treatment Market, By Drug Type:

Pain Relievers

Non-Steroidal Anti-inflammatory Drugs

Nucleoside Analogue Antivirals

  • Hand, Foot, and Mouth Disease Treatment Market, By Route of Administration:

Topical

Oral

Intravenous

  • Hand, Foot, and Mouth Disease Treatment Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

  • Hand, Foot, and Mouth Disease Treatment Market, By Region:

North America

  • United States
  • Canada
  • Mexico

Asia-Pacific

  • China
  • India
  • Japan
  • Australia
  • South Korea

Europe & CIS

  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy

South America

  • Brazil
  • Argentina
  • Colombia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Hand, Foot, and Mouth Disease Treatment Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Hand, Foot, and Mouth Disease Treatment Market

4. Voice of Customer

5. Executive Summary

6. Clinical Trial Analysis

7. Global Hand, Foot, and Mouth Disease Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type (Pain Relievers, Non-Steroidal Anti-inflammatory Drugs, Nucleoside Analogue Antivirals)
    • 7.2.2. By Route of Administration (Topical, Oral, Intravenous)
    • 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 7.2.4. By Company (2021)
    • 7.2.5. By Region
  • 7.3. Market Map

8. North America Hand, Foot, and Mouth Disease Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Hand, Foot, and Mouth Disease Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Mexico Hand, Foot, and Mouth Disease Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Canada Hand, Foot, and Mouth Disease Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel

9. Europe Hand, Foot, and Mouth Disease Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. France Hand, Foot, and Mouth Disease Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Germany Hand, Foot, and Mouth Disease Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. United Kingdom Hand, Foot, and Mouth Disease Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel
    • 9.3.4. Italy Hand, Foot, and Mouth Disease Treatment Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Drug Type
        • 9.3.4.2.2. By Route of Administration
        • 9.3.4.2.3. By Distribution Channel
    • 9.3.5. Spain Hand, Foot, and Mouth Disease Treatment Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Drug Type
        • 9.3.5.2.2. By Route of Administration
        • 9.3.5.2.3. By Distribution Channel

10. Asia-Pacific Hand, Foot, and Mouth Disease Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Hand, Foot, and Mouth Disease Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. India Hand, Foot, and Mouth Disease Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Japan Hand, Foot, and Mouth Disease Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel
    • 10.3.4. South Korea Hand, Foot, and Mouth Disease Treatment Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Drug Type
        • 10.3.4.2.2. By Route of Administration
        • 10.3.4.2.3. By Distribution Channel
    • 10.3.5. Australia Hand, Foot, and Mouth Disease Treatment Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Drug Type
        • 10.3.5.2.2. By Route of Administration
        • 10.3.5.2.3. By Distribution Channel

11. South America Hand, Foot, and Mouth Disease Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Type
    • 11.2.2. By Route of Administration
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Hand, Foot, and Mouth Disease Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Type
        • 11.3.1.2.2. By Route of Administration
        • 11.3.1.2.3. By Distribution Channel
    • 11.3.2. Argentina Hand, Foot, and Mouth Disease Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Type
        • 11.3.2.2.2. By Route of Administration
        • 11.3.2.2.3. By Distribution Channel
    • 11.3.3. Colombia Hand, Foot, and Mouth Disease Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Type
        • 11.3.3.2.2. By Route of Administration
        • 11.3.3.2.3. By Distribution Channel

12. Middle East and Africa Hand, Foot, and Mouth Disease Treatment Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Drug Type
    • 12.2.2. By Route of Administration
    • 12.2.3. By Distribution Channel
    • 12.2.4. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Hand, Foot, and Mouth Disease Treatment Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Drug Type
        • 12.3.1.2.2. By Route of Administration
        • 12.3.1.2.3. By Distribution Channel
    • 12.3.2. Saudi Arabia Hand, Foot, and Mouth Disease Treatment Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Drug Type
        • 12.3.2.2.2. By Route of Administration
        • 12.3.2.2.3. By Distribution Channel
    • 12.3.3. UAE Hand, Foot, and Mouth Disease Treatment Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Drug Type
        • 12.3.3.2.2. By Route of Administration
        • 12.3.3.2.3. By Distribution Channel

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape

  • 15.1. Johnson & Johnson
  • 15.2. GlaxoSmithKline plc.
  • 15.3. Emergex Vaccines Holdings Ltd
  • 15.4. Takeda Pharmaceutical Co Ltd
  • 15.5. CJ HealthCare Corp.
  • 15.6. Adimmune Corp

16. Strategic Recommendations